Italia markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
15,36-0,24 (-1,51%)
Alla chiusura: 05:35PM CET
Schermo intero
Chiusura precedente15,60
Aperto15,67
Denaro15,38 x 0
Lettera15,39 x 0
Min-Max giorno15,33 - 15,72
Intervallo di 52 settimane15,33 - 26,07
Volume1.379.104
Media Volume1.017.253
Capitalizzazione9,091B
Beta (5 anni mensile)N/D
Rapporto PE (ttm)15,86
EPS (ttm)N/D
Prossima data utili24 feb 2022 - 28 feb 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A26,53
  • GlobeNewswire

    GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

    First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity